13F reference period
Q2 2026
Security Snapshot
Contineum Therapeutics, Inc. - Common Stock, $0.001 par value (CTNM) Institutional Ownership
CUSIP: 21217B100
13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026
Institutions Reporting
102
Shares (Excl. Options)
30.55M
Full value: 30,545,688 · shares · 30 Jun 2026Price
$16.39
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- CTNM on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 30,545,688
- Total 13F value
- $500,564,010
- Portfolio coverage rank
- 0%
- Share change
- -47,406
- Value change
- +$11,326,315
- Number of holders
- 102
- Shares outstanding
- 35,342,375
- SEC-reported price per share
- $13.18
- Insider filing price
- $13.18
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CTNM - Contineum Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 21217B100.
- 102 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 90 to 102 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$398.92M
Full value: $398,924,273 · USD · 31 Mar 2026.$500.56M
Full value: $500,564,010 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 102 institutions filings for Q2 2026.
Security key
21217B100
13F reference period
Q2 2026
13F holders
102
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
CTNM full holder history
Contineum Therapeutics, Inc. SEC filings
Contineum Therapeutics, Inc. company facts
Contineum Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 21217B100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
CTNM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 7.9% | $34,403,062 | 2,610,248 | FMR LLC | 30 Sep 2026 | |||
| JANUS HENDERSON GROUP PLC | 7.9% | $27,991,830 | 2,448,979 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 7.1% | -3.7% | $35,477,004 | -$1,248,208 | 2,335,550 | -3.4% | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 |
| BlackRock, Inc. | 6.3% | $33,591,190 | 2,049,493 | BlackRock, Inc. | 30 Jun 2026 | |||
| Johnson & Johnson Innovation - JJDC, Inc. | 5.6% | $26,085,500 | 1,979,173 | Johnson & Johnson Innovation - JJDC, Inc. | 03 Nov 2026 | |||
| FRANKLIN TEMPLETON INC | 5.2% | -17% | $22,875,061 | -$2,346,044 | 1,704,550 | -9.3% | Franklin Templeton, Inc. | 30 Sep 2026 |
| Squadron Capital Management LLC | 5.1% | $22,814,000 | 1,700,000 | Squadron Master Fund LP | 21 Oct 2026 | |||
| Trails Edge Capital Partners, LP | 5.1% | $22,538,125 | 1,679,443 | Trails Edge Capital Partners, LP | 22 Sep 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 4% | -46% | $16,925,917 | -$11,541,109 | 1,296,012 | -41% | RA Capital Management, L.P. | 31 Mar 2026 |
| SECTORAL ASSET MANAGEMENT INC | 5% | $4,297,553 | 950,786 | Jerome G. Pfund | 31 Dec 2024 | |||
| MILLENNIUM MANAGEMENT LLC | 2.8% | -46% | $15,270,617 | -$11,909,557 | 931,709 | -44% | Millennium Management LLC | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC | 3.2% | -54% | $2,776,959 | -$2,944,799 | 699,486 | -51% | Perceptive Advisors LLC | 30 Jun 2025 |
As of 30 Jun 2026,
102
institutional investors reported holding
shares of
Contineum Therapeutics, Inc. - Common Stock, $0.001 par value (CTNM).
This represents
86%
of the company’s total
outstanding shares.
30.55M
Full value: 30,545,688 · shares · 30 Jun 202635.34M
Full value: 35,342,375 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 8% | 2,841,334 | 0% | 0.98% | $46,569,464 |
| Jupiter Topco LLC | 7.7% | 2,734,836 | 0% | 0.02% | $44,769,265 |
| BlackRock, Inc. | 5.8% | 2,064,345 | +209% | 0% | $33,834,614 |
| JOHNSON & JOHNSON | 5.6% | 1,979,173 | 0% | 4.1% | $32,438,645 |
| FRANKLIN RESOURCES INC | 5.2% | 1,839,227 | 0% | 0.01% | $30,144,931 |
| Balyasny Asset Management L.P. | 4.3% | 1,522,793 | -9.7% | 0.05% | $24,958,577 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 1,321,356 | +8.8% | 0% | $21,657,025 |
| PERCEPTIVE ADVISORS LLC | 3.6% | 1,255,592 | 0% | 0.32% | $20,579,153 |
| FMR LLC | 2.9% | 1,040,130 | +28% | 0% | $17,047,731 |
| MILLENNIUM MANAGEMENT LLC | 2.6% | 931,709 | -39% | 0.01% | $15,270,711 |
| GREAT POINT PARTNERS LLC | 2.6% | 921,481 | +15% | 3.6% | $15,103,074 |
| Longaeva Partners L.P. | 2.3% | 812,757 | +11% | 0.38% | $13,321,087 |
| Ikarian Capital, LLC | 2.3% | 807,874 | 0% | 2.2% | $13,241,056 |
| SECTORAL ASSET MANAGEMENT INC | 2.1% | 727,587 | 0% | 8.3% | $11,925,151 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 693,188 | +146% | 0% | $11,364,044 |
| HHLR ADVISORS, LTD. | 1.9% | 669,337 | 0% | 1.3% | $10,970,433 |
| RED TREE MANAGEMENT, LLC | 1.8% | 638,158 | 0% | 7.1% | $10,459,410 |
| Versant Venture Management, LLC | 1.5% | 542,628 | 0% | 5.5% | $8,893,673 |
| GOLDMAN SACHS GROUP INC | 1.4% | 497,255 | +62% | 0% | $8,150,009 |
| Boxer Capital Management, LLC | 1.4% | 494,000 | 0% | 0.61% | $8,096,660 |
| STATE STREET CORP | 1.2% | 425,902 | +321% | 0% | $6,980,534 |
| CITADEL ADVISORS LLC | 1.1% | 396,354 | +13% | 0% | $6,496,242 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.93% | 328,000 | 0.01% | $5,375,920 | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.84% | 296,135 | -1.9% | 0.54% | $4,853,653 |
| ADAR1 Capital Management, LLC | 0.79% | 278,961 | +0.83% | 0.22% | $4,572,171 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Headline period
Q2 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 3,083,482 | $41,352,354 | +$2,859,574 | $13.42 | 17 |
| 2026 Q2 | 30,545,688 | $500,564,010 | +$11,326,315 | $16.39 | 102 |
| 2026 Q1 | 30,555,198 | $398,924,273 | +$6,773,778 | $13.06 | 90 |
| 2025 Q4 | 29,602,152 | $338,263,936 | +$137,435,356 | $11.43 | 80 |
| 2025 Q3 | 17,478,081 | $205,365,503 | +$48,626,432 | $11.75 | 61 |
| 2025 Q2 | 13,856,430 | $55,287,652 | -$6,405,461 | $3.97 | 68 |
| 2025 Q1 | 15,121,377 | $105,552,026 | -$10,223,173 | $6.98 | 62 |
| 2024 Q4 | 15,761,089 | $230,901,673 | +$20,179,605 | $14.65 | 60 |
| 2024 Q3 | 13,713,806 | $258,404,333 | +$11,041,962 | $19.14 | 52 |
| 2024 Q2 | 13,016,510 | $229,220,181 | +$229,145,565 | $17.61 | 49 |